BMC Neurology

Table 1 Summary of study characteristics of the included studies

From: A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)

Observational Studies							Sample Size
Author	Year	Study Design	Dx	Cytokine Origin	Cytokine Analysis	Country	CFS/ME	HC
Fletcher, et al. [20]	2009	Case Control	Fukuda	Serum	ELISA	U.S.A.	40	59
Hardcastle, et al. [21]	2015	Case Control	Fukuda	Serum	MBAA	Australia	41	22
Hornig, et al. [22]	2016	Case Control	Fukuda and CCC	CSF	MBAA	U.S.A.	32	19
Kennedy, et al. [23]	2004	Case Control	Fukuda	Serum	ELISA	United Kingdom	47	34
Landi, et al. [24]	2016	Case Control	Fukuda and/or CCC	Serum	ELISA	U.S.A.	100	79
Montoya J, et al. [25]	2017	Case Control	Fukuda	Serum	MBAA	U.S.A.	186	388
Nakamura, et al. [26]	2010	Case Control	Fukuda	Serum	MBAA	U.S.A.	11	24
Nas K, et al. [27]	2011	Case Control	ICC	Serum	MBAA	Turkey	25	20
Natelson, et al. [28]	2005	Case Control	Fukuda	CSF	MBAA	U.S.A.	44	13
Neu D, et al. [29]	2014	Case Control	Fukuda	Serum	MBAA	Belgium	13	11
Peterson, et al. [30]	2015	Case Control	Fukuda	CSF	MBAA	U.S.A.	18	5
Repka-Ramirez, et al. [31]	2002	Case Control	Fukuda	Nasal Lavage	ELISA	U.S.A.	95	89
Russell, et al. [32]	2016	Case Control	ICC	Serum	ELISA	U.S.A.	50	69
Suhadolnik, et al. [33]	2004	Case Control	Fukuda	Serum	ELISA	U.S.A.	66	62
Tomoda et al. [34]	2005	Case Control	Fukuda	Serum	ELISA	Japan	15	23

Dx CFS/ME diagnostic criteria used, HC healthy control(s), ELISA enzyme-linked immunosorbent assay, MBAA multiplex bead array assay, CCC Canadian Consensus Criteria, ICC International Consensus Criteria, CSF cerebrospinal fluid
This table is a summary of the characteristics of the included studies

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com